Gilberto N. Carmona
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gilberto N. Carmona.
Molecular Pain | 2010
May Hamza; Xiao-Min Wang; Albert Adam; Jaime S. Brahim; Janet Rowan; Gilberto N. Carmona; Raymond A. Dionne
BackgroundKinins play an important role in regulation of pain and hyperalgesia after tissue injury and inflammation by activating two types of G-protein-coupled receptors, the kinin B1 and B2 receptors. It is generally accepted that the B2 receptor is constitutively expressed, whereas the B1 receptor is induced in response to inflammation. However, little is known about the regulatory effects of kinin receptors on the onset of acute inflammation and inflammatory pain in humans. The present study investigated the changes in gene expression of kinin receptors and the levels of their endogenous ligands at an early time point following tissue injury and their relation to clinical pain, as well as the effect of COX-inhibition on their expression levels.ResultsTissue injury resulted in a significant up-regulation in the gene expression of B1 and B2 receptors at 3 hours post-surgery, the onset of acute inflammatory pain. Interestingly, the up-regulation in the gene expression of B1 and B2 receptors was positively correlated to pain intensity only after ketorolac treatment, signifying an interaction between prostaglandins and kinins in the inflammatory pain process. Further, the gene expression of both B1 and B2 receptors were correlated. Following tissue injury, B1 ligands des-Arg9-BK and des-Arg10-KD were significantly lower at the third hour compared to the first 2 hours in both the placebo and the ketorolac treatment groups but did not differ significantly between groups. Tissue injury also resulted in the down-regulation of TRPV1 gene expression at 3 hours post-surgery with no significant effect by ketorolac treatment. Interestingly, the change in gene expression of TRPV1 was correlated to the change in gene expression of B1 receptor but not B2 receptor.ConclusionsThese results provide evidence at the transcriptional level in a clinical model of tissue injury that up-regulation of kinin receptors are involved in the development of the early phase of inflammation and inflammatory pain. The up-regulation of B1 receptors may contribute to acute inflammatory pain through TRPV1 activation.
Diabetologia | 2015
Huanyu Xu; Liron Abuhatzira; Gilberto N. Carmona; Suryakiran Vadrevu; Leslie S. Satin; Abner Louis Notkins
Aims/hypothesismiR-153 is an intronic miRNA embedded in the genes that encode IA-2 (also known as PTPRN) and IA-2β (also known as PTPRN2). Islet antigen (IA)-2 and IA-2β are major autoantigens in type 1 diabetes and are important transmembrane proteins in dense core and synaptic vesicles. miR-153 and its host genes are co-regulated in pancreas and brain. The present experiments were initiated to decipher the regulatory network between miR-153 and its host gene Ia-2β (also known as Ptprn2).MethodsInsulin secretion was determined by ELISA. Identification of miRNA targets was assessed using luciferase assays and by quantitative real-time PCR and western blots in vitro and in vivo. Target protector was also employed to evaluate miRNA target function.ResultsFunctional studies revealed that miR-153 mimic suppresses both glucose- and potassium-induced insulin secretion (GSIS and PSIS, respectively), whereas miR-153 inhibitor enhances both GSIS and PSIS. A similar effect on dopamine secretion also was observed. Using miRNA target prediction software, we found that miR-153 is predicted to target the 3′UTR region of the calcium channel gene, Cacna1c. Further studies confirmed that Cacna1c mRNA and protein are downregulated by miR-153 mimics and upregulated by miR-153 inhibitors in insulin-secreting freshly isolated mouse islets, in the insulin-secreting mouse cell line MIN6 and in the dopamine-secreting cell line PC12.Conclusions/interpretationmiR-153 is a negative regulator of both insulin and dopamine secretion through its effect on Cacna1c expression, which suggests that IA-2β and miR-153 have opposite functional effects on the secretory pathway.
Neuroscience | 2014
Gilberto N. Carmona; Takuya Nishimura; Charles W. Schindler; Leigh V. Panlilio; Abner Louis Notkins
The islet-antigens IA-2 and IA-2β are major autoantigens in type-1 diabetes and transmembrane proteins in dense core vesicles (DCV). Recently we showed that deletion of both IA-2 and IA-2β alters the secretion of hormones and neurotransmitters and impairs behavior and learning. The present study was designed to evaluate the contribution to learning of each of these genes by using single knockout (SKO) and double knockout (DKO) mice in an active avoidance test. After 5 days of training, wild-type (WT) mice showed 60-70% active avoidance responses, whereas the DKO mice showed only 10-15% active avoidance responses. The degree of active avoidance responses in the IA-2 SKO mice was similar to that of the DKO mice, but in contrast, the IA-2β SKO mice behaved like WT mice showing 60-70% active avoidance responses. Molecular studies revealed a marked decrease in the phosphorylation of the cAMP response element-binding protein (CREB) and Ca(2+)/calmodulin-dependent protein kinase II (CAMKII) in the striatum and hippocampus of the IA-2 SKO and DKO mice, but not in the IA-2β SKO mice. To evaluate the role of CREB and CAMKII in the SKO and DKO mice, GBR-12909, which selectively blocks the dopamine uptake transporter and increases CREB and CAMKII phosphorylation, was administered. GBR-12909 restored the phosphorylation of CREB and CAMKII and increased active avoidance learning in the DKO and IA-2 SKO to near the normal levels found in the WT and IA-2β SKO mice. We conclude that in the absence of the DCV protein IA-2, active avoidance learning is impaired.
Leukemia & Lymphoma | 2018
Sreenivasulu Gunti; Sarah E. M. Herman; Raju V.S.R.K. Gottumukkala; Ying Xiong; Clare Sun; Gilberto N. Carmona; Adrian Wiestner; Abner Louis Notkins
Sreenivasulu Gunti , Sarah E.M. Herman , Raju V.S.R.K. Gottumukkala†, Ying Xiong, Clare Sun , Gilberto N. Carmona, Adrian Wiestner and Abner L. Notkins Experimental Medicine Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA; Hematology Branch, National Institute of Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Journal of Translational Medicine | 2018
Lin Wang; Zhong Sheng Sun; Bingwu Xiang; Chi-ju Wei; Yan Wang; Kevin Sun; Guanjie Chen; Michael S. Lan; Gilberto N. Carmona; Abner Louis Notkins; Tao Cai
BackgroundNeurogenin3 (Ngn3) and neurogenic differentiation 1 (NeuroD1), two crucial transcriptional factors involved in human diabetes (OMIM: 601724) and islet development, have been previously found to directly target to the E-boxes of the insulinoma-associated 2 (Insm2) gene promoter, thereby activating the expression of Insm2 in insulin-secretion cells. However, little is known about the function of Insm2 in pancreatic islets and glucose metabolisms.MethodsHomozygous Insm2−/− mice were generated by using the CRISPR-Cas9 method. Glucose-stimulated insulin secretion and islet morphology were analyzed by ELISA and immunostainings. Expression levels of Insm2-associated molecules were measured using quantitative RT-PCR and Western blots.ResultsFasting blood glucose levels of Insm2−/− mice were higher than wild-type counterparts. Insm2−/− mice also showed reduction in glucose tolerance and insulin/C-peptide levels when compared to the wild-type mice. RT-PCR and Western blot analysis revealed that expression of Insm1 was significantly increased in Insm2−/− mice, suggesting a compensatory response of the homolog gene Insm1. Similarly, transcriptional levels of Ngn3 and NeuroD1 were also increased in Insm2−/− mice. Moreover, Insm2−/− female mice showed a significantly decreased reproductive capacity.ConclusionsOur findings suggest that Insm2 is important in glucose-stimulated insulin secretion and is involved in the development pathway of neuroendocrine tissues which are regulated by the transcription factors Ngn3, NeuroD1 and Insm1.
Drug Metabolism and Disposition | 2000
Gilberto N. Carmona; Steven R. Goldberg; David A. Gorelick; Qian-sheng Yu; Edward J. Cone; Charles W. Schindler
Journal of Nutrition | 2005
Sun-Young Lim; John D. Doherty; Kathleen McBride; Nancy J. Miller-Ihli; Gilberto N. Carmona; Ken D. Stark; Norman Salem
Neurocritical Care | 2011
Michael Moussouttas; Edwin W. Lai; Keith Dombrowski; Thanh T. Huynh; John Khoury; Gilberto N. Carmona; Matthew DeCaro; Karel Pacak
Journal of Pharmacology and Experimental Therapeutics | 2003
Alan P. Kozikowski; Kenneth M. Johnson; Olivier Deschaux; Bidhan C. Bandyopadhyay; Gian Luca Araldi; Gilberto N. Carmona; Patrik Munzar; Miles P. Smith; Robert L. Balster; Patrick M. Beardsley; Srihari R. Tella
Journal of Translational Medicine | 2016
Huanyu Xu; Tao Cai; Gilberto N. Carmona; Liron Abuhatzira; Abner Louis Notkins